MDC Associates

What MDC Associates does

MDC Associates, Inc. is a privately held, US-based contract research organization (CRO) specialized in the in vitro diagnostics (IVD) and medical device sector, headquartered in Beverly, Massachusetts. Founded circa 1988-1989 and reorganized under President & CEO Joen T. Johansen in May 2019, the firm delivers integrated clinical, regulatory, and quality consulting services to diagnostic developers across the product lifecycle — from first FDA submission through post-market surveillance. The company's core technology is specialized regulatory and clinical-operations expertise rather than proprietary software or hardware; it operates a network of 200+ clinical sites across the US, Europe, and the Southern Hemisphere to execute studies, and supports an average of 5-10 clinical studies and 4-5 FDA submissions/clearances per year.

The firm's service portfolio is organized into three core solutions — Clinical Services (study design, site selection, monitoring, data management, and post-market evidence generation), Regulatory Services (510(k), De Novo, PMA, Breakthrough Device Designation, IVDR, UKCA, and Health Canada submissions), and Quality Services (QMS/eQMS strategy, audit support, CAPA management, FDA inspection preparation, and 483/Warning Letter remediation) — delivered across three therapeutic-area verticals: Infectious Diseases, Clinical Chemistry & Hematology, and CLIA-waived/PoC/OTC testing. Cumulative client footprints include 70+ infectious disease firms, 40+ clinical chemistry/hematology projects, and 40+ PoC/OTC projects, and the company is an ARPA-H Investor Catalyst Hub spoke in Greater Boston.

MDC generates revenue through project-based professional services engagements, with pricing determined per client engagement based on study complexity, regulatory pathway, site count, and duration. Go-to-market is consultative enterprise field sales driven by content marketing (IVDwise blog and newsletter), active participation and sponsorship at major industry conferences (ESCMID, ASCO, ASM Microbe, ADLM, RAPS Convergence, MedTech, IDWeek, AMP, MEDICA), and direct outreach via Calendly-scheduled consultations. The company serves startup, growth-stage, and established IVD/medtech firms across North America, Europe, the Middle East, South and East Asia, and Oceania.

Name

MDC Associates

Legal name

MDC Associates, Inc.

Website

https://mdcassoc.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

MDC Associates is a specialized IVD-focused CRO providing integrated clinical, regulatory, and quality consulting services to in vitro diagnostics and medical device companies, with over 35 years of FDA submission experience across infectious disease, clinical chemistry, and PoC/OTC verticals.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

Keywords

• Clinical research services
• Regulatory affairs consulting
• Quality systems consulting
• IVD regulatory strategy
• Clinical trial management

Headquarters

HQ city

Beverly

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Clinical Research Services: MDC generates revenue by providing clinical trial management services to IVD and medtech companies, supporting studies from planning through closeout. Revenue is project-based, scoped for each client engagement, with pricing determined by study complexity, number of sites, therapeutic area, and regulatory pathway requirements.
2. Regulatory Affairs Consulting: The company provides regulatory strategy, FDA submissions, global registrations (IVDR, UKCA, Health Canada), and US representative services on a consulting basis. Fees are structured per engagement or project milestone.
3. Quality Systems Consulting: MDC offers quality management system support including QMSR gap assessments, audit preparation, remediation services, and CAPA management. Revenue is generated through consulting engagements, audits, and ongoing support retainer arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

MDC Associates is a full-service Contract Research Organization (CRO) dedicated to in vitro diagnostics (IVD) and medical device companies, providing integrated clinical, regulatory, and quality consulting services. The firm manages clinical studies from design through closeout, prepares and submits FDA and EU regulatory filings (510(k), De Novo, PMA, IVDR, UKCA, Health Canada), and implements quality management systems, audit support, and remediation. Its market focus spans infectious disease diagnostics, clinical chemistry and hematology, and CLIA-waived, point-of-care, and OTC testing.

Product overview

MDC Associates is a full-service IVD CRO (Contract Research Organization) offering integrated clinical, regulatory, and quality services. The company's core offerings include Clinical Services (study execution from planning through closeout), Regulatory Services (FDA and EU regulatory strategy and submissions), and Quality Services (QMS planning, audit support, and remediation). These services are organized across three therapeutic market focuses: Infectious Diseases, Clinical Chemistry & Hematology, and CLIA-Waived/PoC/OTC testing. The company also offers Partnering Services tailored to startup, growth, and established IVD companies. MDC positions itself as an agile, specialized CRO partner with over 35 years of experience helping diagnostic companies navigate regulatory approval and market adoption.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 5-10 clinical studies and 4-5 FDA submissions/clearances per year on average
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• ARPA-H Investor Catalyst HubcoreStrategic or Co-development Partner · 15 December 2023MDC Associates was selected as a spoke for the ARPA-H Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). The hub-and-spoke model is designed to reach diverse nonprofit organizations and Minority-Serving Institutions with the goal of delivering scalable healthcare outcomes. As a spoke, MDC gains access to potential funding and flexible contracting for faster award execution, opportunities to provide input on ARPA-H challenge areas and priorities, and access to networking opportunities and a robust resource library.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Medpace: Medpace is a full-service CRO with deep medical device and diagnostic clinical operations capabilities. While far broader and pharmaceutical-heavy, its medical device/diagnostics practice competes for the same IVD sponsor mandates that MDC serves, especially for larger pivotal studies.
• Eurofins Scientific: Eurofins operates clinical trial laboratory and central laboratory services for IVD and pharma clients, with strong global site support. Its central lab and IVD validation services compete directly with MDC's clinical and regulatory capabilities for diagnostic sponsors running global studies.
• Charles River Laboratories: Charles River provides clinical and regulatory services to medical device and diagnostic clients alongside its larger preclinical and biologics franchise. It competes for mid-to-large IVD sponsors wanting integrated discovery-through-market services, often displacing smaller specialists on enterprise deals.
• IQVIA: IQVIA is the largest global CRO with significant medical device and diagnostic capabilities. It competes against MDC for enterprise IVD clients seeking global trial scale, regulatory expertise, and real-world evidence post-market services.

Direct peers

• NAMSA: NAMSA is a medical device and IVD-focused CRO offering regulatory, clinical, and quality services across the full product lifecycle. It is the closest large-scale analog to MDC's integrated IVD CRO model, with similar therapeutic-area depth (infectious disease, chemistry/hematology, PoC) and FDA-submission expertise.
• Avania (formerly MPI Research): Avania is a medtech-focused CRO providing clinical trial management, regulatory affairs, and post-market services to device and IVD manufacturers. Its sole focus on medical technology directly mirrors MDC's IVD specialization, making it a comparable niche challenger in the same customer segment.
• RCRI (Regulatory & Clinical Research Institute): RCRI is a specialized medical device and IVD CRO offering regulatory strategy, clinical trial management, and quality services. Its tight IVD focus and similar service taxonomy make it a like-for-like competitor for MDC's startup and growth-stage IVD clients.
• ProMedDx Clinical Services: ProMedDx offers clinical research and regulatory services to in vitro diagnostics and medical device manufacturers. Its IVD-centric positioning and similar boutique CRO structure make it a close comparison for smaller specialized engagements MDC targets.

Emerging players

• Advarra: Advarra provides IRB, institutional biosafety, and clinical research technology services to medical device and IVD sponsors. It competes for regulatory and quality-related workflows that overlap with MDC's submissions, IRB coordination, and compliance offerings.
• Clinipace Worldwide: Clinipace is a mid-size CRO with therapeutic-focused clinical and regulatory capabilities, including diagnostics-adjacent engagements. While not solely IVD-focused, it competes for emerging IVD sponsors needing a more nimble alternative to large incumbents.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mdc-associates
• Xx.com/MDC_Assoc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MDC Associates